Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Barr Laboratory BRL -- Ignore unavailable to you. Want to Upgrade?

To: Wolf 2 who wrote (150)	2/16/1999 11:13:00 AM
From: E. Graphs	Respond to of 207

Wolf, There aren't any buys going back as far as 8/12/97 if the site is correct. My guess from watching the stock: There is good support at 33. Since it has been tested, if it holds support at 33 (and today does look good for BRL)and breaks 37/38, it could return to 49... .....and then we'll see. Might start getting back some of my position here, and then if/when it continues to test 33+ I'll add to my position. Good Luck Trading, E!

To: Wolf 2 who wrote (150)	2/17/1999 12:24:00 PM
From: E. Graphs	Read Replies (1) \| Respond to of 207

Prescriptions for Growth iionline.com >> Barr Laboratories (NYSE: BRL) is known for its aggressive patent challenges on branded products. In fact, earlier this week Barr announced that it has initiated a patent challenge against Ortho Pharmaceutical's Ortho-Novum 7/7/7 oral contraceptive, a product with approximately $160 million in sales in 1998. Keep in mind that any generic drug company that successfully challenges a patent is granted a six-month exclusivity in the market. This challenge offers the company an opportunity to add to its line of three proprietary products, including an emergency contraceptive pill approved in September 1998 that is expected to be profitable by the second half of 2000. On February 1, Barr signed an exclusive license agreement with the Medical College of Hampton Roads to acquire the technology and patents related to an innovative, patent protected oral contraceptive product. The product could be launched in late 2002 or early 2003. Meanwhile, it is also challenging Eli Lilly's Prozac patents, a case which is still pending and that Barr intends to take to the U.S. Court of Appeals. A decision from the Appeals Court would probably be rendered in the first quarter of 2000, predicts Gruntal's David Saks, a full year before Prozac's official 2001 expiration. Prozac is the fourth patent the company has challenged; two of the three prior cases, involving Cipro and Tamoxifen, were successful. Meanwhile, Barr has strong positions with its generic versions of Tamoxifen and Warfarin Sodium drugs. According to drug tracking service IMS America, Barr controls 22% of the market with Warfarin Sodium (generic Coumadin). The generic sales of breast-cancer treatment Tamoxifen are expected to grow roughly 7-8% in the second half of the current fiscal year, and benefit from increased promotion of the branded Nolvadex by Zeneca (NYSE: ZEN). As a result of the patent challenge, Barr has 80% of the market distribution for Tamoxifen. Once patent expiration ends in 2002, Saks notes 'Barr's profit margin should jump from a 15% level earned as a distributor, to nearly 70% as a generic manufacturer/marketer, nearly a five-fold improvement.' With these growth drivers, Barr is expected to generate over 30% annual earnings per share growth over the next five years. Analysts expect the company to earn $2.11 per share in fiscal (June) 1999 and $2.68 in 2000. Sales are estimated at $440 million for 1999, up 17% from $377 million in the year-earlier period. At $35, Barr's shares trade at 17 times 1999 estimates and 13 times 2000 forecasts. Saks has a $60 price target for the stock.<<